KRAS and cancer: The possibility that in KRAS and BRAF mutant cancer cells differential signalling mechanisms that involve MEK, supported the mutual exclusivity of these two mutations, lead to the target-specific cancer therapeutics in the form of monoclonal antibodies against EGFR and VEGF receptors.